This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MLND Millendo Therapeutics (MLND) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About Millendo Therapeutics Stock (NASDAQ:MLND) 30 days 90 days 365 days Advanced Chart Get Millendo Therapeutics alerts:Sign Up Key Stats Today's Range$7.07▼$7.1850-Day Range$3.06▼$5.8452-Week Range$0.92▼$16.95Volume48,646 shsAverage Volume1.52 million shsMarket Capitalization$135.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan. Read More Receive MLND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Millendo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MLND Stock News HeadlinesRelease Therapeutics Secures CHF 3.3 Million in Seed FundingAugust 6, 2024 | tmcnet.comA lifesaving therapy for children with a rare disease is now the world’s most expensive drug, raising questions about accessMarch 20, 2024 | msn.comElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it takes for the entire thing to burn right up. It’s a NEW internet service poised to disrupt the entire $3.2 trillion telecom industry. But you may only have this chance if you act before December 31st, 2025. | Banyan Hill Publishing (Ad)Mind Medicine sends psychedelic stocks higher after FDA status for LSD formulationMarch 7, 2024 | msn.comClearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private PlacementJanuary 11, 2024 | markets.businessinsider.comWhy Is Clearmind Medicine (CMND) Stock Up 50% Today?December 5, 2023 | msn.comMaxim Group Maintains Their Buy Rating on Mind Medicine (MMED)November 6, 2023 | markets.businessinsider.comExpert Ratings for Decibel TherapeuticsMarch 15, 2023 | benzinga.comSee More Headlines MLND Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Millendo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Millendo Therapeutics investors own include Elbit Systems (ESLT), UnitedHealth Group (UNH), AbbVie (ABBV), American Water Works (AWK), Bright Health Group (BHG), Black Hills (BKH) and Blackrock Municipal 2030 Target Term Trust (BTT). Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:MLND CIKN/A Webwww.millendo.com Phone734 845 9000FaxN/AEmployees12Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$36.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-91.03% Return on Assets-72.44% Debt Debt-to-Equity RatioN/A Current Ratio6.39 Quick Ratio6.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.78 per share Price / Book4.01Miscellaneous Outstanding Shares19,043,000Free FloatN/AMarket Cap$135.78 million OptionableNot Optionable Beta0.48 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:MLND) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… and it's all thanks to President Trump. His administr...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Millendo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Millendo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.